SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

1AD (1AD) News

Follow 1AD (1AD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 1AD Asset market Sector Markets 90 days 2 Updated Sep 18, 2026, 03:02 AM UTC Open live news feed
M AdAlta says Oribiotech customer deal validates its IRO manufacturing plan AdAlta (ASX:1AD) says its automated IRO manufacturing strategy has gained commercial validation after Oribiotech secured a major long-term customer under a 10-year agreement worth up to US$120 million. EQUITY | Sep 18, 2026, 03:02 AM UTC M AdAlta partner gets China approval for armored CAR-T mesothelioma therapy Shanghai Cell Therapy Group, AdAlta’s co-development partner, received approval to provide BZDS1901 first-in-class armored CAR-T therapy to eligible patients with advanced mesothelioma under China’s special access scheme GEOPOLITICS | Sep 02, 2026, 03:06 AM UTC